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BACKGROUND: Post-hoc analyses of AFP response and progression and their relationship with objective measures of response and
survival were performed in patients from REACH.
METHODS: Serum AFP was measured at baseline and every 3 cycles (2 weeks/cycle). Associations between AFP and radiographic
progression and efficacy end points were analysed.
RESULTS: Median percent AFP increase from baseline was smaller in the ramucirumab than in the placebo arm throughout
treatment. Time to AFP progression (HR 0.621; P < 0.0001) and to radiographic progression (HR 0.613; P < 0.0001) favoured
ramucirumab. Association between AFP and radiographic progression was shown at 6 (OR 6.44, 95% CI 4.03, 10.29; P < 0.0001) and
12 weeks (OR 2.28, 95% CI 1.47, 3.53; P= 0.0002). AFP response was higher with ramucirumab compared with placebo (P < 0.0001).
More patients in the ramucirumab arm experienced tumour shrinkage and AFP response compared with placebo. Survival was
longer in patients with AFP response (13.6 months) than in patients without (6.2 months), irrespective of treatment (HR 0.457, P <
0.0001).
CONCLUSIONS: Treatment with ramucirumab prolonged time to AFP progression, slowed AFP increase and was more likely to
induce AFP response. Similar benefits in radiographic progression and response correlated with AFP changes.
British Journal of Cancer https://doi.org/10.1038/s41416-018-0103-0
INTRODUCTION
Liver cancer is the sixth most commonly diagnosed cancer
worldwide and the second most common cause of cancer death.1
Hepatocellular carcinoma (HCC) represents approximately 90% of
primary liver cancers and occurs most frequently in patients with
cirrhosis from chronic hepatitis B or C virus infection or alcohol
abuse.2
Alpha-fetoprotein (AFP) level has long been known to correlate
with HCC prognosis and has historically played a role in diagnosis.
Elevated AFP levels are associated with larger tumours, bilobar
involvement, portal vein invasion, poorly differentiated histology
and decreased median survival.3 Measurement of AFP level has
been incorporated into some HCC prognostic scoring systems.4,5
While high levels of AFP are recognised as a poor prognostic
factor, the utility of AFP response or progression during anticancer
treatment is still unclear. There are limited studies in patients with
HCC correlating AFP kinetics with treatment response during
locoregional therapy or while on sorafenib and no published
results of patients on second-line treatment.
Vascular endothelial growth factor (VEGF) is overexpressed in
HCC and associated with poorer clinical outcomes, suggesting
VEGF-mediated signalling is important in HCC pathogenesis and is
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a therapeutic target.6–8 Ramucirumab is a recombinant immuno-
globulin G, subclass 1 monoclonal antibody that specifically binds
to the extracellular domain of VEGFR-2 with high affinity,
preventing binding of VEGF ligands and receptor activation.9
REACH, a global, randomised, double-blinded placebo-controlled
Phase 3 study, evaluated the efficacy and safety of single-agent
ramucirumab for patients with advanced HCC after prior treat-
ment with sorafenib (N= 565).10 Significant improvement in
overall survival (OS) in the intent-to-treat (ITT) population was
not achieved. However, a clinically meaningful improvement in OS
was observed in patients with elevated baseline AFP levels (≥400
ng/mL [n= 250]) treated with ramucirumab vs placebo (OS 7.8 vs
4.2 months, respectively; hazard ratio (HR) 0.67, P= 0.006).
In the REACH study, AFP values were collected at baseline and
during treatment. Post-hoc analyses of AFP response and
progression, and correlations with other measures of efficacy
including time to progression (TTP), objective response rate (ORR),
and OS, were performed.
PATIENTS AND METHODS
Patient selection, randomisation and masking
The details of eligibility for inclusion in the REACH trial were
previously described.10
Procedures
Patients received either ramucirumab 8mg/kg (ImClone Systems
Corporation, Branchburg, NJ, USA) (n= 283) or placebo (n= 282)
intravenously every 2 weeks until disease progression, unaccep-
table toxicity or withdrawal of consent. All patients received
supportive care. Predefined dose modifications were allowed to
manage treatment-related toxicity.10 Local radiological imaging
was performed at baseline, every 6 weeks over the first 6 months
of treatment and every 9 weeks thereafter. In the event of
ramucirumab/placebo dose delays or missed doses, disease
assessment and imaging studies were to be undertaken according
to the original study schedule (i.e. every 6 weeks after first dose for
the first 6 months and every 9 weeks thereafter), regardless of the
actual number of on-study treatments received.
Statistical definitions
TTP was defined as the time from randomisation to radiographic
progression; radiographic response was assessed by protocol-
defined criteria based on Response Evaluation Criteria in Solid
Tumors 1.1 (appendix); ORR was defined as the proportion of
patients who achieved complete response (CR) or partial response
(PR) as their best overall response (BOR).
OS was defined as the time from randomisation to death from
any cause.
Serum AFP levels were measured locally at baseline (within
2 weeks prior to randomisation), and every 3 cycles, i.e. every
6 weeks until treatment discontinuation, and at short-term follow-
up. AFP progression was defined as ≥20% increase from non-zero
baseline and absolute increase ≥10 ng/mL. For the small number
of patients (n= 4; 2 in the ramucirumab arm, 2 in the placebo
arm) with a true baseline AFP of zero, AFP progression was
defined as absolute increase AFP ≥ 10 ng/mL from zero baseline.
These definitions were chosen to limit the risk of non-significant
variations in AFP levels being considered AFP progression. AFP
response was assessed in the population subset with baseline
AFP ≥ 1.5 upper limit of normal (ULN) and was defined as ≥20%
decrease from baseline. This threshold of a minimum level of
baseline AFP was selected to allow for a meaningful analysis since
patients with very low levels of baseline AFP experiencing non-
significant variations in AFP levels during treatment could result in
large percent changes. Changes of 20 and 50% from baseline have
been examined in previous studies.11–13
Statistical analysis
This post hoc analysis was conducted within the ITT population of
REACH. The baseline distribution of patients by AFP level was
plotted for comparison between arms. After taking log10 of
baseline AFP values, the frequency (patient count) was plotted for
each arm. AFP response rate is presented with 95% confidence
interval (CI) and was compared using the
Cochran–Mantel–Haenszel test. Percent change in AFP from
baseline was analysed for each arm at each time point up to
Cycle 12. Analyses evaluated the association between the events
of AFP progression and radiographic progression in each AFP level
measurement time interval (Fisher’s exact test and odds ratio
[OR]).
Time to AFP progression and time to radiographic progression
between treatment arms were evaluated by the Kaplan–Meier
method and tested by a stratified log-rank test. HR was generated
using a stratified Cox proportional hazard model. AFP response
rate is presented with 95% CI and compared using
Cochran–Mantel–Haenszel test. The statistical analysis was done
using the SAS® software Version 9.2.
AFP percent changes observed in patients in the ramucirumab
arm were compared to those in the placebo arm at Cycles 3, 6, 9
and 12 by non-parametric Wilcoxon rank-sum tests.
RESULTS
Baseline patient and disease characteristics in the ITT population
were well balanced between treatment groups.10 Baseline
characteristics of patients in whom AFP response was assessed
(with baseline AFP above 1.5 ULN, n= 417) were also well
balanced and, apart from baseline, AFP showed no meaningful
differences from the baseline characteristics of the ITT population
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Fig. 1 Distribution of patients by baseline AFP level in each arm. a
Patients treated with placebo and best standard of care. b Patients
treated with ramucirumab and best standard of care. AFP alpha-
fetoprotein
AFP kinetics in patients with hepatocellular carcinoma














(Table S1). Additional details on the REACH study population have
been disclosed previously.10 After log transformation of baseline
AFP, the distribution of patients by log AFP for each treatment arm
appeared similar in both treatment arms. A t-test on the log-
transformed baseline AFP levels did not show any significant
difference in baseline AFP levels between two arms (Fig. 1).
Changes in AFP relative to baseline were analysed and defined
as either AFP progression or response, or neither, as per the
Patients and methods section. A Kaplan–Meier plot of time to AFP
progression for patients treated with ramucirumab vs placebo is
shown in Fig. 2. The median time to AFP progression was
3.2 months in the ramucirumab arm (95% CI 2.7, 4.6, n= 279) and
1.6 months in the placebo arm (95% CI 1.5, 2.3, n= 281) with an
HR of 0.621 (P < 0.0001).
Consistent with the results on time to AFP progression, patients
treated with ramucirumab were more likely to experience an AFP
response (decrease) at any time post-baseline compared to
patients treated with placebo (ramucirumab: 27.8% vs placebo:
10.8%; P < 0.0001) and less likely to experience AFP progression
(increase) at any time post-baseline compared to those treated
with placebo (ramucirumab: 62.4% vs placebo: 75.9%; P= 0.0033).
The difference in the percentage of patients with AFP response or
progression between arms was significant when AFP response
and progression were defined as a 20% (P < 0.0001) or 50% (P=
0.0004) change from baseline. No meaningful differences in the
rates of AFP response were observed for patients with baseline
≥400 ng/mL compared to those with AFP < 400 ng/mL, suggesting
that AFP response was independent of the magnitude of baseline
AFP (data not shown).
Waterfall plots of best percent change in AFP from baseline for
patients treated with ramucirumab or placebo also support the
results of the analyses on AFP response and progression (Fig. 3a).
The proportion of patients who experienced an increase in AFP
was not only lower in the ramucirumab arm but the magnitude of
the increase also appeared smaller when compared with the
placebo arm. Of note, 23 patients on the placebo arm also
experienced an AFP response. An assessment of baseline
characteristics for these patients did not identify any meaningful
differences from the rest of the cohort, and other definitions of
AFP response would not eliminate the presence of patients with
AFP response in the placebo arm and likely represent true
spontaneous responses.
To further assess the kinetics of AFP during treatment, AFP
percent changes from baseline were calculated, and the median
percent change from baseline evaluated by treatment arm
(Fig. 4a). At each AFP assessment time point following baseline
at Cycles 3, 6, 9 and 12, the median percent increase in AFP level
from baseline was smaller in the ramucirumab arm (4, 0, 3, 33%)
than in the placebo arm (37, 50, 99, 78%), respectively, and AFP
percent change was significantly smaller in the ramucirumab arm
at Cycles 3, 6 and 9.
Correlation of AFP changes with measures of radiographic
response or progression
Kaplan–Meier plots of time to AFP progression and time to
radiographic progression were similar in appearance (Fig. 2). The
median time to radiographic progression was 3.5 months on the
ramucirumab arm (95% CI 2.8, 4.5, n= 283) and 2.6 months in the
placebo arm (95% CI 1.6, 2.8, n= 282, HR 0.613, P < 0.0001). A high
association between AFP progression and radiographic progres-
sion occurring within each tumour assessment period was also
observed (OR 6.4, 95% CI 4.0, 10.3, P < 0.0001 for up to Week 6, OR
2.3, 95% CI 1.5, 3.5, P= 0.0002 for Weeks 6–12) (Table 1).
Median percent change in AFP was further assessed in
subgroups of patients defined by their best overall radiographic
response (objective response [complete response/partial response
(CR/PR)], disease control [CR/PR/stable disease (SD)] and progres-
sive disease [PD]). For patients with a best overall radiographic
Ramucirumab
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response of CR/PR, the observed median percent change in AFP
was a decrease in both treatment arms, with more patients in the
ramucirumab arm experiencing an objective response compared
to placebo (Fig. 4b). However, this should to be interpreted with
caution given the small number of patients with best response of
CR/PR and the differences between the groups were not
statistically significant (Fig. 4b). For patients with a BOR of disease
control (CR/PR/SD), the median percent AFP increase from
baseline for patients in the ramucirumab arm was lower than
what was observed in the placebo arm at each cycle (Fig. 4c), with
AFP percent changes being statistically different for the two arms
at Cycles 6 and 9. In patients experiencing a best response of PD
defined by radiographic progression, AFP increase from baseline
for patients on the ramucirumab arm was significantly lower than
what was observed on the placebo arm at Cycle 3 (Fig. 4d). There
was no data available at Cycle 9 or 12 for this subgroup of patients
as most patients with a best response of progression had already
discontinued treatment.
Waterfall plots of radiographic tumour response by treatment
arm and the relationship with AFP response (yes vs no) are shown
in Fig. 3b. A higher proportion of patients experienced a
radiographic response in the ramucirumab arm compared with
the placebo arm. Most patients with a radiographic response (14
on RAM, 4 on PBO) also experienced an AFP response (10 on RAM,
3 on PBO).
Overall survival by AFP response
Additional analyses on the relationship between AFP response
and OS were performed. A Kaplan–Meier plot of OS for patients
(baseline AFP > 1.5 × ULN), irrespective of treatment arm, with
either an AFP response (n= 80) or no AFP response (n= 337) is
shown in Fig. 5a. The median OS for patients with an AFP response
was significantly longer than that for patients without AFP
response (13.6 vs 6.2 months, HR= 0.457, 95% CI 0.338, .616; P
< 0.0001).
Kaplan–Meier plots of OS by treatment arm in patients with
either an AFP response (Fig. 5b) or no AFP response (Fig. 5c) are
shown in Fig. 5. In patients with an AFP response, there was no
statistically significant survival benefit of ramucirumab treatment
over placebo over the course of treatment (up to 28 months).
Notably, in patients without an AFP response, a potentially
significant survival benefit was observed for patients treated with
ramucirumab compared to placebo (7.2 vs 5.2 months, HR= 0.758,
95% CI 0.600, 0.958; P= 0.020), suggesting that even patients with
elevated AFP (>1.5 × ULN) who do not have an AFP response may
derive a benefit from ramucirumab treatment.
Patients with no AFP response































































































Fig. 3 Waterfall plots of response for patients by treatment arm. a Best percent change in AFP from baseline measurements by treatment arm.
b Best percent change in radiographic tumour response, and relationship with AFP response. AFP alpha fetoprotein
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Further analyses showed that 11 patients completely normal-
ised their AFP level, 8 from the ramucirumab arm, and 3 from the
placebo arm. The OS for these 11 patients who completely
normalised their AFP level was significantly longer than the OS for
patients who had AFP response without completely normalising
their AFP level (n= 111) (25.6 vs 10.6 months, respectively, HR=
0.147, P= 0.0019).
DISCUSSION
Serum AFP has long been recognised as both a diagnostic and
prognostic marker.14–17 However, assessing AFP kinetics during
treatment has been limited. Some retrospective studies have been
performed in patients undergoing locoregional therapy, where an
AFP response has been associated with a longer survival following
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Fig. 4 AFP percent change from baseline by cycle. Medians of AFP percent changes from baseline were plotted every three cycles for patients
from the ITT population with baseline AFP ≥ 1.5 ULN by treatment arm. a for all patients; b for patients with best overall response of CR/PR; c
for patients with best overall response of CR/PR/SD; d for patients with best overall response of PD. aITT population with baseline AFP ≥ 1.5
ULN. *Indicates a statistical difference between the two groups by non-parametric Wilcoxon rank-sum tests. AFP alpha-fetoprotein, CR
complete response, ITT intention to treat, NA not available, PD progressive disease, PR partial response, SD stable disease, Q1 lower quartile,
Q3 upper quartile
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setting, AFP response has been evaluated in patients being
treated with chemotherapy as well as sorafenib where a response
is often associated with a survival advantage.13,20,21 In these
previously published studies, there were fewer than 200 patients
evaluated, only one of them derived data from a randomised
study and none was placebo-controlled. Here we report post-hoc
analyses of AFP response and progression in 565 patients enrolled
in the REACH study. Five hundred and sixty patients with
assessable changes in AFP were included in our analysis. An
additional advantage of having a placebo arm in our REACH study
was to allow assessment of AFP kinetics due to underlying HCC
rather than treatment-related. However, in most studies examin-
ing systemic therapy, including REACH, the number of patients
who experience an AFP response has been quite low. Molecularly
targeted agents more commonly result in disease stability, and
restricting treatment to patients experiencing an AFP response
would exclude a large proportion of patients with stable or slowed
progression of AFP levels, who would also derive survival benefit
from continued treatment.
In the current analysis of REACH, there was an observed benefit
with ramucirumab in delaying time to AFP progression, inducing
more frequent and deeper AFP response and lesser AFP
progression. AFP changes also correlated with radiographic
response and progression. The phase 2 biomarker study of
ramucirumab as first-line monotherapy in patients with advanced
HCC showed that an AFP decrease was more likely in patients who
experienced a radiographic response and an AFP increase more
likely in patients with radiographically progressive or non-
evaluable disease.22 Similar correlations have been made between
AFP and other radiographic measures of response with other
systemic treatments including sorafenib.13,23–26 The observations
of changes in AFP and measures of objective response in REACH
continue to support a correlation between AFP and objective
radiographic measures of tumour assessment.
The results presented here support the notion that the
ramucirumab antitumour effect is not restricted to patients with
AFP or objective tumour response but rather has some activity in
all tumours with varying degree. In the ramucirumab arm, more
Table 1. Radiographic progression and AFP progression by tumour measurement period
Radiographic progression event No radiographic progression event P-value Odds ratio (95% CI)
Up to 6 weeks, N 97 463
AFP progression, n (%) 56 (58) 81 (18)
No AFP progression, n (%) 41 (42) 382 (83)
<0.0001 6.4 (4.0, 10.3)
6–12 weeks, N 159 246
AFP progression, n (%) 63 (40) 55 (22)
No AFP progression, n (%) 96 (60) 191 (78)
0.0002 2.3 (1.5, 3.5)
AFP alpha-fetoprotein, CI confidence interval
AFP progression was defined as ≥20% increase from non-zero baseline and absolute increase ≥10 ng/mL, or absolute increase AFP ≥ 10 ng/mL from zero
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patients experienced both an AFP and a radiographic response
compared to placebo. We also observed a shift in the rest of the
treated population favouring ramucirumab compared to placebo.
More patients in the ramucirumab arm experienced stable AFP or
SD compared to placebo. Even in patients who only experienced
AFP or radiographic progression, the amplitude of the observed
AFP or tumour increase was generally lower.
However, while changes in AFP may correlate with other
measures of tumour assessment, neither changes in AFP nor other
objective measures of tumour response have been good
surrogates to predict OS.27 In REACH, while an AFP response
was associated with significantly longer OS, analyses support that
OS benefit extends to a larger population. Notably, in patients
with an elevated baseline AFP (>1.5 × ULN) a potential OS benefit
was still observed in ramucirumab-treated patients compared to
placebo, even when AFP responders were excluded; this is likely
driven by the much larger proportion of patients who experience
disease stability rather than regression. While this re-demonstrates
that an elevated baseline AFP can identify the subset of
patients most likely to derive an OS benefit, the finding also
shows that AFP response is inadequate to select patients most
likely to derive a survival benefit. Based on the studies presented
here, the lack of an AFP response for a patient should not be used
in isolation to judge clinical benefit of systemic treatments like
ramucirumab.
Of note, a number of patients on placebo also experienced an
AFP response. While the reasons for spontaneous AFP response in
the placebo arm are unknown, we note that a similar proportion
of patients on the placebo arm also experienced a radiographic
response. Other limitations of the results presented here are due
to the fact that these were post-hoc analyses performed on a
phase 3 study that did not meet its primary end point.
In conclusion, exploratory analyses of REACH show that
changes in AFP over time appear to correlate with other
measures of objective progression and may help predict patient
response, but the utility of AFP to make treatment decisions
needs to be validated through a prospective study. Further
assessment of the potential benefit of ramucirumab in patients
with elevated baseline AFP is being validated in the ongoing
REACH-2 study.
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